288 related articles for article (PubMed ID: 23587606)
1. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
Braun S; Russo L; Zeidler J; Linder R; Hodgkins P
Clin Ther; 2013 May; 35(5):673-85. PubMed ID: 23587606
[TBL] [Abstract][Full Text] [Related]
2. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
3. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
4. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
5. [Age- and Gender-specific Costs as Well as Drug Therapies of ADHD Patients].
Klora M; Zeidler J; Lublow D; Linder R; Verheyen F; von der Schulenburg JM
Gesundheitswesen; 2016 Jul; 78(7):e23-9. PubMed ID: 26695543
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
7. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
Treceño C; Martín Arias LH; Sáinz M; Salado I; García Ortega P; Velasco V; Jimeno N; Escudero A; Velasco A; Carvajal A
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017
[TBL] [Abstract][Full Text] [Related]
8. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Štuhec M; Locatelli I; Švab V
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
[TBL] [Abstract][Full Text] [Related]
9. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
10. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
[TBL] [Abstract][Full Text] [Related]
11. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
12. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
[TBL] [Abstract][Full Text] [Related]
13. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
[TBL] [Abstract][Full Text] [Related]
14. An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom.
Raman SR; Marshall SW; Gaynes BN; Haynes K; Naftel AJ; Stürmer T
Psychiatr Serv; 2015 Jun; 66(6):617-24. PubMed ID: 25726974
[TBL] [Abstract][Full Text] [Related]
15. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
16. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
[TBL] [Abstract][Full Text] [Related]
17. The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs.
Maia CR; Stella SF; Mattos P; Polanczyk GV; Polanczyk CA; Rohde LA
Braz J Psychiatry; 2015; 37(1):67-70. PubMed ID: 25806553
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Jensen PS; Garcia JA; Glied S; Crowe M; Foster M; Schlander M; Hinshaw S; Vitiello B; Arnold LE; Elliott G; Hechtman L; Newcorn JH; Pelham WE; Swanson J; Wells K
Am J Psychiatry; 2005 Sep; 162(9):1628-36. PubMed ID: 16135621
[TBL] [Abstract][Full Text] [Related]
19. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
